STRO-002 for Ovarian & Endometrial Cancers

Recruiting at26 trial locations

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Sutro Biopharma, Inc.

No Placebo Group

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

This trial tests the safety and effectiveness of STRO-002, a new IV drug, in adults with advanced ovarian and related cancers that have not responded to other treatments. The drug targets a specific protein on cancer cells to help stop their growth.

Research Team

Arturo Molina, MD

Principal Investigator

Sutro Biopharma

Eligibility Criteria

This trial is for adults with certain types of ovarian and endometrial cancers who have relapsed or progressed after treatment. They should be in good physical condition, have a life expectancy over 3 months, and not exceed three prior cancer treatments. Those with severe chronic diseases, more than three lines of previous treatments, or specific cancer subtypes are excluded.

Inclusion Criteria

My diagnosis is confirmed by a pathology report.

I am fully active or can carry out light work.

I am 18 years old or older.

Exclusion Criteria

My cancer has spread to my brain or its coverings.

I do not have severe eye, lung, heart, brain disorders, or other serious health issues.

My cancer did not respond to initial platinum-based chemotherapy.

Treatment Details

Interventions

• STRO-002 (Monoclonal Antibodies)

Trial Overview The study tests STRO-002, an experimental drug targeting FolRα given every 3 weeks intravenously. It's a Phase 1 trial focusing on the safety profile, how the body processes the drug (pharmacokinetics), and its preliminary effectiveness against ovarian and endometrial cancers.

Participant Groups

Group I: STRO-002 treatment Experimental Treatment 1 Intervention

Dose Escalation: STRO-002 at increasing dose levels Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg

Who Is Running the Clinical Trial?

Sutro Biopharma, Inc.

Lead Sponsor

Trials

7

Recruited

1,100+